Why the study?
Prior studies on coronary no-reflow evaluated outdated reperfusion therapies, leaving its frequency and prognostic value unclear in the era of drug-eluting stents and newer antithrombotic drugs.
Does coronary no-reflow increase the risk of adverse clinical and cerebral events in patients with acute myocardial infarction undergoing PCI with current drug-eluting stents and third-generation P2Y12 inhibitors?
Does coronary no-reflow increase the risk of adverse clinical and cerebral events in patients with acute myocardial infarction undergoing PCI with current drug-eluting stents and third-generation P2Y12 inhibitors?
Coronary no-reflow remains a significant predictor of adverse clinical events at 1 year in AMI patients, even in the era of contemporary drug-eluting stents and potent P2Y12 inhibitors.
Answers are grounded in this paper and cite their sources.
No-reflow may warrant closer monitoring in contemporary AMI PCI; extends prior observations to current DES and P2Y12 inhibitors.
BACKGROUND: The frequency and prognostic value of coronary no-reflow (CNR) was investigated in studies that have used an outdated reperfusion therapy in terms of stent technology and antithrombotic drugs. We assessed the association of CNR with adverse outcomes in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and newer antithrombotic drugs, ticagrelor or prasugrel. METHODS: inhibitors. CNR was defined as Thrombolysis in Myocardial Infarction (TIMI) blood flow grade ≤ 2 at the end of PCI. The primary end point was 1-year incidence of net adverse clinical and cerebral events-a composite end point of death of any cause, myocardial infarction, stroke or major bleeding. RESULTS: CNR was diagnosed in 130 patients (4.2%). The primary end point occurred in 28 patients in the CNR group and 354 patients in the reflow group (cumulative incidence 23.2% and 12.8%; adjusted hazard ratio = 1.53, 95% confidence interval 1.01-2.33; P = 0.049). The 1-year incidences of death or myocardial infarction (14.6% vs. 7.6%; P = 0.003), myocardial infarction (8.8% vs. 3.9%; P = 0.007) and major bleeding (10.9% vs. 5.6%; P = 0.008) were significantly higher in patients with CNR than patients with reflow. The risk of adverse events in patients with CNR was highest within the first 30 days after PCI. CONCLUSION: receptor inhibitors, CNR was associated with a higher risk of adverse outcomes at 1 year.
No takes yet. Share an insight, caveat, or question.
Ndrepepa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: